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Objective: To study parvovirus B19 infection in immunocompromised subjects such as renal transplantation recipients. 
Methods: Two cases of B19 infection in renal transplant recipients have been included in the study. The outcome of 
the infection has been studied by both serologic and virologic methods. A monitoring of the DNAemia was done by a 
nested PCR in endpoint titration assays. 
Results: In  one patient with severe anemia an acute B19 infection was diagnosed by PCR 26 days after the transplant; 
a high level of DNAemia persisted until an intravenous immunoglobulin treatment. Then a sharp decrease of the 
DNAemia was shown, without full clearance of B19 virus. In  a lymphocyte suspension from the organ donor, B19 DNA 
was detected. In the other patient, who recovered spontaneously from anemia, a persistent B19 infection was 
demonstrated at day 106 after transplantation and was still demonstrable after 470 days. 
Conclusions: A high level of B19 DNAemia was associated with symptomatic infection, with severe anemia, whereas 
low-level DNAemia was long-lasting in  asymptomatic subjects with impaired immunologic responses. The endpoint 
titration assay by nested PCR was very useful for the monitoring of B19 infection, particularly following the therapeutic 
intravenous immunoglobulin administration. 
Key words: Parvovirus B19, renal transplantation, persistent B19 infection, semiquantitative PCR 
Twenty years afier its discovery in sera from 
asyiiiptoniatic subjects [I  1, the human parvovirus B19 
is known to be the cause of several pathologic 
conditions, ranging from erythema infectiosmit to 
transient aplastic crisis or hydrops fetalis 12-51. In 
imiiiunoconi~~etent people, acute B19 infections 
generally occur, but it is now well documented that in 
iniiiiuiiocompromised subjects B19 virus can persist, 
leading to severe acute or chronic anemia 15-81; more- 
over, two cases of persistent €31 4, infection5 in ininiuno- 
conipetent subjects have also been described [9-1 11. 
Corresponding author and reprint requests: 
Alberta Azzi, lstituto di Microbiologia, Universita di Firenze, 
Wale Morgagni 48, 50134 Firenze, Italy 
Tel: 39 55 411081 Fax: 39 55 4223895 
Accepted 29 February 1996 
Renal transplantation recipients should be con- 
sidered at risk of B19 infection because of the 
ini~iiunosuppressive treatments; however, two cases 
only of U19 infection in such patients have been 
reported up to now. The first observation dates back t o  
1986 [l2] and concerns a case of B19 infection 
associated with a transient bone marrow dysfunction, 
1 month after the transplantation. The second obser- 
vation described in 1993 (131 concerns a case of B19 
infection associated with pure red cell aplasia and 
peripheral pancytopenia, which occurred 1 year after 
the renal transplant. In addition, one of the sera first 
detected as I319 virus positive by Cossart et al. [ I ]  was 
from a patient 1 week after renal transplantation, It is 
probable that the rate of B19 infection in such patients 
is underestimated, because B19 virus is s o  far not 
sufficiently known worldwide. 
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Here we report two cases of B19 infection in two 
renal transplant recipients, characterized by different 
clinical outcomes, detected simultaneously in the 
spring of 1994. A semi-quantitative application of the 
nested polymerase chain reaction (PCK) allowed the 
monitoring of the virologic outcome of B19 infection, 
especially in a patient who required an intravenous 
immunoglobulin (IVIG) treatment. 
MATERIALS AND METHODS 
Patients and samples examined 
Two patients, TF, a 53-year-old man, and BK, a 47- 
year-old woman, under-went a cadaveric kidney trans- 
plantation on 1 January 1994 and 21 February 1994, 
respectively, at the Department of Renal Transplanta- 
tion of the Careggi Hospital in Florence. The transplant 
was successful in both patients, with good primary 
function. The imniunosuppression included prednisone 
and cyclo-sporin. TF received in addition azathioprine 
from day 11 after the transplant, but this additional 
treatment was then stopped because of an inhibitory 
effect on either the erythroid or the myeloid compart- 
ment of the bone marrow; nevertheless the anemia 
persisted. Bladder bleeding occurred 4 days after the 
transplant in patient BK, and two transfusions of 
packed red blood cells were required. A few days later, 
the patient developed a severe hypoplastic anemia 
(hematocrit 15.2%, reticulocyte count 0.2-0.596). The 
bone marrow was hypo-cellular with giant pronornio- 
blasts. The patient was treated at first with IVIG (200 
mg/kg) twice a week, without clinical improvement; 
therefore, on day 56 after transplant, the doses were 
increased to 400 mg/kg per day for 15 days. A few days 
after the start of this treatment, an increase of the 
reticulocyte count and the resolution of the anemia 
were observed. 
A series of 20 serum samples were drawn from 
patient BR,  on dnys 26 to 380 after transplantation, for 
the diagnosis and monitoring of B19 infection; in 
addition, a serum sample taken before transplantation 
was available. Moreover, a bone marrow sample at day 
+ 66 and two throat swabs (day + 56 and day + 94) were 
also obtained from the same patient for €319 DNA 
detection. A series of four sera were drawn from TR, 
on days 103 to 391 after renal transplantation. 
Finally, lymphocytes from the two kidney donors 
were also analyzed for B19 DNA presence, and a serum 
sample from a blood donor, 1 month after the donation 
to BR, was analyzed for B19 DNA and for anti-B19 
IgM and IgG. 
Virologic and serologic methods 
A dot-blot hybridization assay with a digoxigenin- 
labeled probe [14] and a nested P C R  [I51 have been 
used for B19 DNA detection. In order to eliminate 
inhibitors of the Taq polymerase, serum samples were 
heated at 72 "C for 45 s, whereas DNA from the bone 
marrow sample (200 pL) and the throat swabs (400 pL) 
was extracted by the phenol/chloroform method, after 
digestion with proteinase K. A semiquantitative PCR 
was also used to evaluate the concentration of B19 
DNA in the sera at different times during the infection. 
An endpoint titration method, with a cloned B19 
DNA as an external standard, was used: the B19 DNA 
sequence, 1112 bp long, amplified by the external 
primers in the nested PCR,  was cloned in the plasmid 
pGEM-T, which was used to transform E.coli JM 109. 
This plasmid was subsequently employed as external 
I319 DNA standard in the nested PCR. Dilutions 
containing 0.71 fg, 0.071 fg, 0.0071 fg and 0.00071fg 
of the B19 DNA target and 10-fold serial dilutions of 
the sera to be titered were used in the P C R  assay. The 
endpoint was given by the highest dilution of the 
standard DNA which resulted in a visible band after 
electrophoresis in agarose gel stained with ethidium 
bromide (0.5 pg/mL). Triplicate assays were carried 
Appropriate positive and negative controls were 
performed in each PCR,  and guidelines to prevent 
false-positive results were adopted. Pretreatments of 
sample, preparation of P C R  mix, addition of the 
samples to the mix, PCK cycling and electrophoresis 
were performed in five different laboratories. 
Two commercial kits for anti-B19 IgM and IgG 
detection were used: the kit from Ferring using a 
synthetic peptide as antigen, and the kit from Dako 
using a recombinant antigen obtained in a baculovirus- 
insect cell expression system and an antibody capture 
assay for anti-B19 IgM detection. The results were 
always concordant. 
out. 
Only the serum samples drawn from the patient B R  
before the beginning of the treatment with high doses 
of IVIG gave positive results in the dot-blot hybrid- 
ization assay with a B19 DNA-specific probe, digoxi- 
genin labeled, whereas by the nested P C R  all serum 
samples from patient BR,  as well as four out of five 
serum samples from patient TR, obtained after renal 
transplantation, were positive for B19 DNA. However, 
the use of a semiquantitative PCR showed that the viral 
load in these samples was very different (Table 1). 
In fact, a high-level DNAemia was demonstrable 
in the first serum sample available, day + 26, and per- 
sisted until day + 57, when the treatment with high 
doses of IVIG began. At day +60  a decrease of 
B19 DNAemia was already evident. However, B19 
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DNAemia persisted at very low concentration and was 
still demonstrable more than 1 year after the transplant. 
In contrast, in the patient TF the level of B19 
DNAeinia was steadily low in the first three seruni 
samples; in a sample drawn more than 1 year after 
transplantation, B19 IINA was undetectable by the 
nested PCK, but it was again positive in the last sample 
available 570 days after transplantation. 
In addition, a bone marrow sample, taken from 
patient BK at day + 66, was morphologically normal, 
but PCK positive for B19 DNA. 
A characteristic pattern of the antibody response 
was observed in both patients: in patient BR,  anti-B19 
IgG was still negative in the first saiiiple examined aftei- 
transplantation, and low IgG levels were detectable 
anti1 the IVIG administration at high dose; following 
this treatment, in fact, high levels of anti-B19 IgG 
appeared and were still detectable in a patient serum at 
day + 92. A slight decrease was detectable in sera at days 
+ 106 and + 121 and, 1 year later, the anti-B19 IgG was 
again undetectable, whereas the anti-B19 1gM persisted 
at  high levels, unmodified from the beginning of the 
infection. The patient TR also presented constant high 
levels of anti-B19 IgM but very low levels of IgC, 
which in the last two samples was undetectable. 
Both patients were B19 antibody negative before 
transplantation, and B19 IINA was absent in sera drawn 
at  the time of the transplant. 
I n  order to investigate the source of 1319 trails- 
mission, lymphocyte suspensions from the two kidney 
donors, stored frozen under liquid nitrogen, were tested 
for B19 DNA presence: the lymphocytes of the young 
donor to the patient B R  gave weakly positive results in 
the nested P C R  for B19 DNA, whereas the lympho- 
cytes from the donor to the patient TR gave negative 
results. To exclude the possibility of a false-positive 
result due to contamination of the PCK, the Iynipho- 
cyte suspension of B R  stored in two different vials has 
been analyzed at different times. 
With the aim of assessing the possibility of respira- 
tory shedding of B19 virus by patient BR,  and thus the 
risk of transmission of the infection to hospital staff 
[16] or other contacts, during the highly vireniic phase 
a throat swab at day + 56, from a little ulcerative lesion, 
was tested for B19 DNA and was I'CK positive, 
whereas the throat swab at day + 94 was negative. 
DISCUSSION 
The results reported here confirm that ininiuno- 
depressed subjects are at risk of persistent I319 infection 
which may cause anemias of different severity. 111 fact, 
in one case only high doses of IVIG were required for 
clinical recovery. The difkrent clinical outcome of B19 
infection in these two patients could be related to 
different routes of transniission and to different viral 
loads transmitted or, in addition, to different host 
conditions at  the time of- the infection, which are 
unknown in TR's case. 
In  both patients, however, B 19 infection persisted 
after the recovery fi-om anemia, as shown by the 
persistence of very low levels of IINAernia. 
U19 DNA was demonstrated in a lymphocyte 
suspension from the kidney donor of the first patient 
(BR). It is likely that residual I319 DNA from the 
whole blood was still present in the lymphocyte 
suspension, so that it could be drtected by the highly 
sensitive nested PCK. The lymphocyte suspension 
from the kidney donor of the patient TR was B19 
I INA 1iegative.These results strongly suggest that 13 19 
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infection has been transmitted to the patient B R  in the 
transplanted organ, but do not allow us to exclude a 
role of the transplanted kidney in the transmission of 
B19 infection to TR, even if it seems more likely that 
this patient became infected by the common respira- 
tory route. 
As previously reported, dot-blot hybridization 
assay was able to detect B19 viremia during the acute 
phase only, when high amounts of B19 particles were 
free in the blood, but failed to demonstrate persistent 
infections characterized by very low viral load [17,18]. 
Indeed, persistent B19 infection could be shown by the 
nested PCR only, which could detect 10 viral genomes. 
The nested PCR,  however, used as a qualitative 
assay cannot differentiate between acute and late or 
persistent infections and can neither identify differences 
in virus concentration which could be related to 
symptomatic or asymptomatic conditions nor indicate 
a level of viremia that niay warrant initiation of antiviral 
therapy [19]. A number of different quantitative or semi- 
quantitative PCR applications have been developed in 
this regard: competitive methods based on the use of an 
internal standard are at present considered the most 
accurate quantitative assays; however, the very simple 
and traditional method of endpoint titration may be a 
suitable alternative for detecting wide variation in the 
amount of target DNA sequences in series of specimens 
taken for monitoring virus infection following thera- 
peutic treatments [20]. 
In this study the use of the nested P C R  in endpoint 
titration assays for monitoring B19 infection allowed 
us to assess the early therapeutic effect of IVIG. In 
addition, the results suggest that a low-level €31 9 
viremia, of about 5000 viral particledml, may be 
associated with persistent asymptomatic BI9  infection. 
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